糖尿病药物市场规模、份额、成长分析（按糖尿病类型、药物类型、最终用户和地区划分）- 2025 年至 2032 年产业预测

全球糖尿病药物市场预计将在 2023 年达到 712 亿美元，从 2024 年的 761.1 亿美元成长到 2032 年的 1,298 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

由于糖尿病盛行率不断上升、创新疗法不断进步以及医疗保健格局的不断演变，全球糖尿病药物市场正经历强劲增长。全球人口老化正在创造巨大的市场机会，因为老年人更容易罹患糖尿病。此外，都市化和生活方式的改变导致糖尿病风险增加，进一步推动了市场扩张。认知度的提高和早期发现正在推动糖尿病治疗。个人化和精准医疗的趋势正在推动客製化治疗方案的製定，以提高疗效。人工智慧、机器学习、物联网和区块链等技术的整合正在彻底改变药物研发和疾病管理。这些技术创新提供即时监控和洞察，从而提高治疗依从性，改善糖尿病护理中患者的整体预后。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管格局
• 客户和购买标准分析
• 管道分析
• 疾病流行病学

糖尿病治疗药物市场规模（依糖尿病类型及复合年增长率）（2025-2032）

• 市场概况
• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

糖尿病治疗药物市场规模（按药物类型和复合年增长率）（2025-2032）

• 市场概况
• 口服抗糖尿病药物
• 注射型抗糖尿病药物

糖尿病治疗药物市场规模（按最终用户和复合年增长率划分）（2025-2032）

• 市场概况
• 医院
• 诊所
• 个人使用

糖尿病治疗药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比比较（2022-2024 年）

主要企业简介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Merck & Co.（USA）
• AstraZeneca（UK）
• Boehringer Ingelheim（Germany）
• Takeda Pharmaceutical Company（Japan）
• Johnson & Johnson（USA）
• Novartis（Switzerland）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Roche（Switzerland）
• Bayer AG（Germany）
• AbbVie（USA）
• Daiichi Sankyo（Japan）
• Gilead Sciences（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Biocon（India）

结论和建议

Global Diabetes Therapeutics Market size was valued at USD 71.2 billion in 2023 and is poised to grow from USD 76.11 billion in 2024 to USD 129.8 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global diabetes therapeutics market is experiencing robust growth due to increasing prevalence of diabetes, innovative treatment advancements, and evolving healthcare dynamics. A rising aging population worldwide creates significant market opportunities, as older individuals are more susceptible to diabetes. Additionally, urbanization and lifestyle changes are contributing to heightened diabetes risks, further driving market expansion. Enhanced awareness and early detection are motivating individuals to seek diabetes therapies. The trend towards personalized and precision medicine is fostering tailored treatment solutions that enhance effectiveness. Technological integration, including AI, machine learning, IoT, and blockchain, is revolutionizing drug discovery and disease management. These innovations provide real-time monitoring and insights, thereby promoting better treatment adherence and improving overall patient outcomes in diabetes care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Therapeutics Market Segments Analysis

Global Diabetes Therapeutics Market is segmented by Diabetes Type, Drug Type, End User and region. Based on Diabetes Type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes. Based on Drug Type, the market is segmented into Oral Antidiabetics and Injectable Antidiabetics. Based on End User, the market is segmented into Hospitals, Clinics and Personal Use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetes Therapeutics Market

The global demand for diabetes therapeutics is being significantly driven by the rising prevalence of both type 1 and type 2 diabetes. This demand is further amplified by an aging population, as older individuals are more susceptible to developing diabetes. Additionally, the escalating rates of obesity, coupled with sedentary lifestyles and unhealthy dietary choices, contribute to market growth by leading to higher levels of insulin resistance and various metabolic disorders. These factors collectively underscore the urgent need for effective diabetes management solutions, propelling the expansion of the diabetes therapeutics market on a worldwide scale.

Restraints in the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market faces notable challenges due to the substantial expenses associated with the ongoing management of both type 1 and type 2 diabetes. Effective treatment often necessitates a lifelong commitment to purchasing insulin, medications, therapies, and glucose monitoring equipment, which can pose a significant financial burden. Individuals lacking adequate health insurance or access to quality healthcare services often struggle to afford necessary diabetes therapeutics, particularly in the absence of reimbursement options. Furthermore, the escalating costs associated with novel biologics and personalized medicine are creating barriers to innovation within the diabetes therapeutics sector, hindering advancements and limiting access for patients.

Market Trends of the Global Diabetes Therapeutics Market

The Global Diabetes Therapeutics market is witnessing a significant trend towards the adoption of personalized and precision medicine, focusing on individualized treatment approaches that cater to distinct genetic profiles, metabolic variations, and lifestyle factors. This shift aims to address the root causes of diabetes by improving insulin sensitivity and overall therapeutic efficacy. With advancements in biotechnology and a growing emphasis on tailored healthcare solutions, these innovative therapies are becoming increasingly accessible and cost-effective, fostering greater acceptance and adherence among patients. As a result, this trend is poised to reshape the landscape of diabetes management by enhancing treatment outcomes and patient experiences.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Diabetes Therapeutics Market Size by Diabetes Type & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Oral Antidiabetics
• Injectable Antidiabetics

Global Diabetes Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Personal Use

Global Diabetes Therapeutics Market Size & CAGR (2025-2032)

• North America (Diabetes Type, Drug Type, End User)
  • US
  • Canada
• Europe (Diabetes Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diabetes Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diabetes Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diabetes Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations